User Tools

Site Tools


idh_wildtype_glioma

see Diffuse astrocytoma IDH wildtype

see Glioblastoma IDH wildtype.

High grade gliomas with mutations in the isocitrate dehydrogenase (IDH) gene family confer longer overall survival relative to their IDH wild type

IDH-wildtype = IDH negative = no mutation = poor prognosis.

It appears that IDH mutant gliomas are a distinct disease entity, having a different genetic and epigenetic basis as compared to IDH wild-type (unmutated) gliomas.

The outcome of patients with anaplastic gliomas varies considerably depending on single molecular markers, such as mutations of the isocitrate dehydrogenase (IDH) genes, as well as molecular classifications based on epigenetic or genetic profiles.

Remarkably, 98% of the RNA within a cell is not translated into proteins. Of those, especially microRNAs (miRNAs) have been shown not only to have a major influence on physiologic processes but also to be deregulated and prognostic in malignancies.

To find novel survival markers and treatment options Schliesser et al., performed unbiased DNA methylation screens that revealed 12 putative miRNA promoter regions with differential DNA methylation in anaplastic gliomas. Methylation of these candidate regions was validated in different independent patient cohorts revealing a set of miRNA promoter regions with prognostic relevance across data sets. Of those, miR-155 promoter methylation and miR-155 expression were negatively correlated and especially the methylation showed superior correlation with patient survival compared to established biomarkers.Functional examinations in malignant glioma cells further cemented the relevance of miR-155 for tumor cell viability with transient and stable modifications indicating an onco-miRNA activity. MiR-155 also conferred resistance towards alkylating temozolomide and radiotherapy as consequence of nuclear factor kappa (NFκB) activation.Preconditioning glioma cells with an NFκB inhibitor reduced therapy resistance of miR-155 overexpressing cells. These cells resembled tumors with a low methylation of the miR-155 promoter and thus mir-155 or NFκB inhibition may provide treatment options with a special focus on patients with IDH wildtype tumors 1).


Zhang et al., found that the combination of SHOX2 expression and IDH genotype status identified a subset of low grade glioma LGG patients with IDH wild type (IDHwt) and low SHOX2 expression with considerably favorable survival 2).

1)
Schliesser MG, Claus R, Hielscher T, Grimm C, Weichenhan D, Blaes J, Wiestler B, Hau P, Schramm J, Sahm F, Weiß EK, Weiler M, Baer C, Schmidt-Graf F, Schackert G, Westphal M, Hertenstein A, Roth P, Galldiks N, Hartmann C, Pietsch T, Felsberg J, Reifenberger G, Sabel MC, Winkler F, von Deimling A, Meisner C, Vajkoczy P, Platten M, Weller M, Plass C, Wick W. Prognostic relevance of miRNA-155 methylation in anaplastic glioma. Oncotarget. 2016 Nov 18. doi: 10.18632/oncotarget.13452. [Epub ahead of print] PubMed PMID: 27880937.
2)
Zhang YA, Zhou Y, Luo X, Song K, Ma X, Sathe A, Girard L, Xiao G, Gazdar AF. SHOX2 is a Potent Independent Biomarker to Predict Survival of WHO Grade II-III Diffuse Gliomas. EBioMedicine. 2016 Nov;13:80-89. doi: 10.1016/j.ebiom.2016.10.040. PubMed PMID: 27840009.
idh_wildtype_glioma.txt · Last modified: 2019/06/13 08:50 by administrador